Estrogen Receptor is the driving transcription factor in about 75% of all breast cancers,
which is the target of endocrine therapies, but drug resistance is a common clinical problem …

Acute myelogenous leukemia (AML) is an aggressive disease associated with drug
resistance and relapse. To improve therapeutic strategies, it is critical to better understand …

Acute myeloid leukaemia (AML) is a heterogeneous disease with one of the worst survival
rates of all cancers. The bone marrow microenvironment is increasingly being recognised as …

We previously demonstrated vast expansion of hypoxic areas in the leukemic
microenvironment and provided a rationale for using hypoxia-activated prodrugs. PR104 is …

Since their description and identification in leukemias and solid tumors, cancer stem cells
(CSC) have been the subject of intensive research in translational oncology. Indeed, recent …

Immunotherapy aims to activate the cancer patient's immune system for cancer therapy. The
whole process of the immune system against cancer referred to as the “cancer immunity …

Abstract Phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR)
are two key components of the PI3K/Akt/mTOR signaling pathway. This signal transduction …

Conventional strategies are not particularly successful in the treatment of leukaemia, and
identification of signalling pathways crucial to the activity of leukaemia stem cells will provide …

Despite high remission rates after therapy, 60% to 70% of patients with acute myeloid
leukemia (AML) do not survive 5 years after their initial diagnosis. The main cause of …

The interactions between hematopoietic cells and the bone marrow (BM) microenvironment
play a critical role in normal and malignant hematopoiesis and drug resistance. These …